The use of anti-HER2 conjugated QDs was applied for immune-labeling of breast and lung cancer cells and was reported to be superior in a panel of lung cancer cells with the differential HER2 expression proposing their potential pertinence in early identification of cancer biomarkers (Rakovich et al., 2014). The gene discussed is ERBB2; the disease is lung carcinoma.